Literature DB >> 19388998

A contemporary standard for morbidity and outcome after radical cystectomy.

Vijay A C Ramani1, Stephen J Bromage, Noel W Clarke.   

Abstract

OBJECTIVE: To report the temporal changes in peri-operative outcome over an extended period in patients undergoing radical cystectomy (RC) for all causes, irrespective of the previous treatment or pathology; and to establish a current standard of peri-operative outcome for RC by analysis of contemporary operative mortality rates (2000-5) factored for risk factors that might predict outcome. PATIENTS AND METHODS: All patients undergoing RC between 1970 and 2005 were analysed; this was an unselected single-centre series and included patients previously treated by definitive radiotherapy, chemotherapy, and cases of RC where the primary tumour involved the bladder but was not of bladder origin.
RESULTS: In all, 846 patients had a RC, of whom 647 had a bladder primary tumour and 199 a primary tumour elsewhere (gynaecological, colorectal and others). There was a progressive reduction in 30- and 60-day mortality rates, such that the current peri-operative mortality (1999-2005) was 0.4% and 2.6%, respectively. There was a significant reduction in the re-operation rate over the decades (P=0.01), which is currently 4.7%. Patient age was a significant factor in 30- and 60-day mortality rates (P<0.001 for both) but there was no significant association between either American Society of Anesthesiologists grade or T stage with complication rates (P=0.61 and 0.12, respectively).
CONCLUSION: There has been a progressive reduction in mortality related to RC, associated with both cases of RC and pelvic exenteration. The contemporary standard for 30-and 60-day mortality rates for these operations is 0.4% and 2.6%, respectively.

Entities:  

Mesh:

Year:  2009        PMID: 19388998     DOI: 10.1111/j.1464-410X.2009.08506.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Three-gene signature predicts disease progression of non-muscle invasive bladder cancer.

Authors:  Pildu Jeong; Yun-Sok Ha; In-Chang Cho; Seok-Joong Yun; Eun Sang Yoo; Isaac Yi Kim; Yung Hyun Choi; Sung-Kwon Moon; Wun-Jae Kim
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

2.  GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer.

Authors:  Yun-Sok Ha; Chunri Yan; Pildu Jeong; Won Tae Kim; Seok-Joong Yun; Isaac Yi Kim; Sung-Kwon Moon; Wun-Jae Kim
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

3.  Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients.

Authors:  Mieke van Hemelrijck; Andreas Thorstenson; Philip Smith; Jan Adolfsson; Olof Akre
Journal:  BJU Int       Date:  2013-07-26       Impact factor: 5.588

4.  What should be the patient's preference regarding the choice of hospital in the case of radical cystectomy? Evaluation of early complications after open radical cystectomy in a medium and high volume setting in one hospital.

Authors:  Jens Mani; Stefan Vallo; Maximilian P Brandt; Kilian M Gust; Claudia Bartsch; Johannes Daechert; Igor Tsaur; Georg Bartsch; Axel Haferkamp
Journal:  Patient Prefer Adherence       Date:  2016-10-28       Impact factor: 2.711

5.  Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience.

Authors:  Thanh-Tuan Nguyen; Olivier Huillard; Yohann Dabi; Julien Anract; Mathilde Sibony; Marc Zerbib; Evanguelos Xylinas
Journal:  Front Surg       Date:  2018-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.